article thumbnail

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

PharmaVoice

Today, we’re speaking to Simone Steiner, Transgene’s new chief technology officer, about how the company is transitioning from early- to late-stage testing and advancing its manufacturing capabilities Oncology vaccines are gaining traction in the clinic as potential game changing treatments for cancer.

Vaccines 243
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Kennedy Jr. Industry groups have also raised serious concerns. BIO President and CEO John F.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Pharmaceutical Technology

June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Credit: viewimage/Shutterstock.

article thumbnail

Under the Weather: Unpacking the Impact of the 2024-2025 Influenza Season

Pharmacy Times

Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains. Targeted public health strategies are needed to improve vaccine access, education, and trust, particularly in underserved communities.

article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.

article thumbnail

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock.

article thumbnail

DoH – Abu Dhabi and Sanofi link for vaccine development

Pharmaceutical Technology

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Credit: Department of Health Abu Dhabi.